Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Carbone

Showing results (111-120 of 651) with videos related to

Pageof 66
Sort By:
Annual Review of Medicine|January 1, 1993
Antioncogenes and human cancerD P Carbone, J D Minna
The Journal of Infusional Chemotherapy|January 1, 1995
Taxol plus radiation for head and neck cancerD I Rosenthal, D P Carbone
European Journal of Cancer & Clinical Oncology|March 1, 1986
Adjuvant hormonotherapy for breast cancerJ L Grem, P P Carbone
Cancer Research|November 1, 1971
Chemotherapeutic implications of staging in Hodgkin's diseaseV T DeVita, P P Carbone
Gynecologic Oncology|August 1, 1974
Endometrial cancer: approach to development of effective chemotherapyP P Carbone, S K Carter
Minerva Urologica|March 1, 1983
[Ureteral obstruction due to secondary neoplasms]P Carbone, T Cammarota, R Fiore
Minerva Stomatologica|November 1, 1985
[Substitutive metal-acrylic endoprosthesis of the mandible]E M Casabona, G Margarino, P Carbone
Journal Des Maladies Vasculaires|January 1, 1992
[Results of ambulatory and hemodynamic treatment of venous insufficiency (CHIVA cure)]J M Fichelle, P Carbone, C Franceschi
Minerva Chirurgica|July 15, 1985
[Oncologic maxillo-facial surgery]E M Casabona, M Scala, P Carbone
Lung Cancer (Amsterdam, Netherlands)|March 1, 2023
Patients' voice and passion lead to successful clinical trial, KISEKI study; Comments on "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy"Naoki Furuya, Kai He, David P Carbone
Pageof 66

Showing results (111-120 of 651) with videos related to

Sort By:
Pageof 66
Annual Review of Medicine|January 1, 1993
Antioncogenes and human cancerD P Carbone, J D Minna
The Journal of Infusional Chemotherapy|January 1, 1995
Taxol plus radiation for head and neck cancerD I Rosenthal, D P Carbone
European Journal of Cancer & Clinical Oncology|March 1, 1986
Adjuvant hormonotherapy for breast cancerJ L Grem, P P Carbone
Cancer Research|November 1, 1971
Chemotherapeutic implications of staging in Hodgkin's diseaseV T DeVita, P P Carbone
Gynecologic Oncology|August 1, 1974
Endometrial cancer: approach to development of effective chemotherapyP P Carbone, S K Carter
Minerva Urologica|March 1, 1983
[Ureteral obstruction due to secondary neoplasms]P Carbone, T Cammarota, R Fiore
Minerva Stomatologica|November 1, 1985
[Substitutive metal-acrylic endoprosthesis of the mandible]E M Casabona, G Margarino, P Carbone
Journal Des Maladies Vasculaires|January 1, 1992
[Results of ambulatory and hemodynamic treatment of venous insufficiency (CHIVA cure)]J M Fichelle, P Carbone, C Franceschi
Minerva Chirurgica|July 15, 1985
[Oncologic maxillo-facial surgery]E M Casabona, M Scala, P Carbone
Lung Cancer (Amsterdam, Netherlands)|March 1, 2023
Patients' voice and passion lead to successful clinical trial, KISEKI study; Comments on "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy"Naoki Furuya, Kai He, David P Carbone
Pageof 66